Hoffmann-la Roche Inc.

U3 Pharma Gmbh

Prothena Biosciences Limited

Jens Niewoehner

Guy Georges

Ekkehard Moessner

Olaf Mundigl

Tilman Schlothauer

Stefan Dengl

Ulrich Goepfert

Hendrik Knoetgen

Adrian Hugenmatter

Hubert Kettenberger

Michael Molhoj

Joerg Moelleken

Monika Baehner

Fiona Grueninger

Thomas Emrich

Anton Jochner

Kevin Brady

Ulrich Brinkmann

Thomas U Hofer

Laurent Lariviere

Tina Weinzierl

Maximiliane Koenig

Erhard Kopetzki

Mike Rothe

Georg Tiefenthaler

Peter Maier

Johannes Bange

Patricia Aus Dem Siepen

Christian Klein

Robin McDaid Barbour

Hans-Willi Krell

Petra Rueger

Wagner Marcelo Zago

Gang Xu

Dirk Ponsel

Sandra Miller

Francesca Ros

Cuiying Shao

Engin Toksoez

Julia Krueger

Kate Dora Games-Thiel

Tarlochan S Niijar

The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Trispecific antibodies specific for HER2 and a blood brain barrier receptor and methods of use

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.

Anti-transferrin receptor antibodies with tailored affinity

The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to STEAP-1

Humanized anti-Tau(pS422) antibodies and methods of use

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles

Herein is reported a method for producing a fusion-polypeptide comprising the seeps of a) cultivating a mammalian cell comprising a nucleic acid encoding a variant fusion-polypeptide wherein the amino acid sequence of the fusion-polypeptide has been modified by replacing in a pro-fusion-polypeptide the endogenous protease cleavage site between the pro-peptide and the fusion-polypeptide with an exogenous (with respect to the origins of the parts of the fusion-polypeptide) or artificial protease cleavage site, and b) recovering the fusion-polypeptide or fusion-pro-polypeptide from the cell or the cultivation median and thereby producing the (recombinant) fusion-polypeptide.

Recombinant polypeptide production methods

Humanized anti-tau(pS422) antibodies and methods of use

The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).

Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Herein is reported a method for producing a fusion-polypeptide comprising the steps of a) cultivating a mammalian cell comprising a nucleic acid encoding a variant fusion-polypeptide wherein the amino acid sequence of the fusion-polypeptide has been modified by replacing in a pro-fusion-polypeptide the endogenous protease cleavage site between the pro-peptide and the fusion-polypeptide with an exogenous (with respect to the origins of the parts of the fusion-polypeptide) or artificial protease cleavage site, and b) recovering the fusion-polypeptide or fusion-pro-polypeptide from the cell or the cultivation medium and thereby producing the (recombinant) fusion-polypeptide.

Growing community of inventors

Munich, Germany

Jens Niewoehner